FDA Approves Trial for CBD-Based Drug for Opioid Addiction

The U.S. Food & Drug Administration (FDA) said a CBD-based treatment for opioid use disorder can be used in clinical trials, Ananda Scientific Inc., the drug’s maker, announced this week.

Ananda Scientific said FDA granted an investigational drug designation (IND) for Nantheia ATL5, a liquid administered through the biotech pharma company’s proprietary delivery technology.

The IND approval is the fourth for the Nantheia product line, “and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications,” said R. Zaidi, ANANDA’s Chief Executive Officer.

Trials at UCLA

“This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,”Zaidi said of the clinical trial for Nantheia ATL5. To be funded by the National Institute on Drug Abuse, the trial is planned at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles (UCLA).

Read more on Hemp Today

Posted in Uncategorized.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.